Electric car brands offer 11,000 discounts in sales scramble
SMMT Stock | USD 17.85 0.04 0.22% |
Slightly above 51% of Summit Therapeutics' private investors are presently thinking to get in. The analysis of the overall investor sentiment regarding Summit Therapeutics PLC suggests that some traders are interested. Summit Therapeutics' investing sentiment can be driven by a variety of factors including economic data, Summit Therapeutics' earnings reports, geopolitical events, and overall market trends.
Summit |
Car makers are discounting electric vehicle prices by an average of 11,000 per car to boost sales, amid warnings that demand from private buyers remains weaker than expected.
Read at finance.yahoo.com
Summit Therapeutics PLC Current Investor Sentiment
Panic Vs Confidence
51
Panic | Confidence |
Today, several news technology companies offer sentiment data to assist traders in manufacturing news sentiment indicators for investment decisions. We partner with these technology firms in helping retail investors build forecasting models that use Summit Therapeutics' input sentiment indicators derived from textual data and news published on major financial information outlets and social sites. These indicators can be used to analyze time-dependent numerical information representing public perception toward Summit Therapeutics PLC.
News SentimentBearish | Hype SentimentBearish | Insider SentimentAcquiring |
Summit Therapeutics Investor Sentiment by Other News Outlets
Investor sentiment, mood or attitude towards Summit Therapeutics can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Summit Therapeutics PLC Historical Investor Sentiment
Investor biases related to Summit Therapeutics' public news can be used to forecast risks associated with an investment in Summit. The trend in average sentiment can be used to explain how an investor holding Summit can time the market purely based on public headlines and social activities around Summit Therapeutics PLC. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
Summit Therapeutics' market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for Summit Therapeutics and other traded tickers. The bigger the bubble, the more accurate the estimated score. Higher bars for a given day show more participation in the average Summit Therapeutics news discussions. The higher the estimate score, the more favorable the investor's outlook on Summit Therapeutics.
Summit Therapeutics Maximum Pain Price Across January 3rd 2025 Option Contracts
Summit Therapeutics' options can also be used to analyze investors' bias and current market sentiment in the context of behavioral finance. For example, Max pain usually refers to a trading concept that asserts that market manipulation can cause the market price of Summit Therapeutics close to the expiration of its current option contract to expire worthlessly. According to most research, about 35% of options are not executed, with roughly 50% traded out before expiration. So, Max pain occurs when market makers reach a net favorable position across all options at a strike price where option holders stand to lose the most money. By contrast, option sellers may reap the most after selling more options than buying, causing them to expire worthlessly. Please continue to view the detailed analysis of Summit Therapeutics' options.
Summit Therapeutics Fundamental Analysis
We analyze Summit Therapeutics' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Summit Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Summit Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Return On Equity
Return On Equity Comparative Analysis
Summit Therapeutics is currently under evaluation in return on equity category among its peers. Return on Equity or ROE tells company stockholders how effectually their money is being utilized or reinvested. It is a useful ratio when analyzing company profitability or the management effectiveness given the capital invested by the shareholders. ROE shows how efficiently a company utilizes investments to generate income.
Summit Therapeutics PLC Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Summit Therapeutics stock to make a market-neutral strategy. Peer analysis of Summit Therapeutics could also be used in its relative valuation, which is a method of valuing Summit Therapeutics by comparing valuation metrics with similar companies.
Peers
Summit Therapeutics Related Equities
CDIO | Cardio Diagnostics | 12.20 | ||||
NKTX | Nkarta | 7.33 | ||||
KRON | Kronos Bio | 2.11 | ||||
CGEM | Cullinan Oncology | 1.72 | ||||
ZVSA | ZyVersa Therapeutics | 0.93 | ||||
SONN | Sonnet Biotherapeutics | 1.35 | ||||
KZR | Kezar Life | 1.47 | ||||
ELEV | Elevation Oncology | 1.75 | ||||
PHIO | Phio Pharmaceuticals | 5.26 | ||||
ZURA | Zura Bio | 6.00 | ||||
ATNF | 180 Life | 6.19 | ||||
OCEA | Ocean Biomedical | 8.33 |
Additional Tools for Summit Stock Analysis
When running Summit Therapeutics' price analysis, check to measure Summit Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Summit Therapeutics is operating at the current time. Most of Summit Therapeutics' value examination focuses on studying past and present price action to predict the probability of Summit Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Summit Therapeutics' price. Additionally, you may evaluate how the addition of Summit Therapeutics to your portfolios can decrease your overall portfolio volatility.